Should the Number of Metastatic Pelvic Lymph Nodes be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer?
FIGO
IIIC
cervical cancer
cut-off
lymph node
number of lymph nodes
number of metastatic lymph nodes
staging system
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Jun 2020
12 Jun 2020
Historique:
received:
23
04
2020
revised:
05
06
2020
accepted:
10
06
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Lymph node status has become part of the new staging system for cervical cancer (CC). It has been shown that patients staged as IIIC1 had heterogeneous prognoses and, in some cases, experienced better outcomes than patients with lower stages. We evaluated the impact of the number of metastatic pelvic lymph nodes (MPLNs) among patients with stage IIIC1 cervical cancer. Survival analyses were conducted in order to identify the best cut-off prognostic value relative to the number of MPLNs. Disease free survival (DFS) was considered the main outcome. 541 patients were included in the study. Eighty-nine patients were of stage IIIC1. The best prognostic cut-off value of the number of MPLNs was 2. Patients with >2 MPLNs ( Using a cut-off value of 2, the number of MPLNs could better predict prognostic outcomes within stage IIIC1 cervical cancer and have potential implications for therapeutic decision-making in the treatment of patients with stage IIIC1 CC.
Identifiants
pubmed: 32545508
pii: cancers12061552
doi: 10.3390/cancers12061552
pmc: PMC7352475
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncol Lett. 2010 Jan;1(1):3-11
pubmed: 22966247
Int J Clin Oncol. 2011 Feb;16(1):33-8
pubmed: 20842404
Ginekol Pol. 2019;90(6):336-345
pubmed: 31276186
Ann Surg Oncol. 2017 Aug;24(8):2311-2318
pubmed: 28608117
Int J Clin Oncol. 2016 Aug;21(4):741-747
pubmed: 26857458
Gynecol Oncol. 2020 May;157(2):423-428
pubmed: 32139148
Gynecol Oncol. 2010 Apr;117(1):53-8
pubmed: 20061005
Gynecol Oncol. 2020 Jan;156(1):85-92
pubmed: 31744640
Ann Transl Med. 2020 Apr;8(7):485
pubmed: 32395529
Curr Med Sci. 2018 Aug;38(4):567-574
pubmed: 30128863
Cancer Res Treat. 2018 Jul;50(3):964-974
pubmed: 29081219
Int J Gynecol Cancer. 2018 Jun;28(5):1020-1028
pubmed: 29727351
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S43-103
pubmed: 17161167
J Gynecol Oncol. 2018 Jul;29(4):e62
pubmed: 29770631
Eur J Surg Oncol. 2017 Apr;43(4):710-716
pubmed: 27890348
Int J Clin Oncol. 2007 Jun;12(3):165-75
pubmed: 17566838
Gynecol Oncol. 2015 Jan;136(1):48-53
pubmed: 25451695
Int J Gynecol Cancer. 2020 May;30(5):602-606
pubmed: 32156715
J Surg Oncol. 2011 Apr;103(5):406-10
pubmed: 21400524
Int J Cancer. 2017 Sep 1;141(5):1042-1051
pubmed: 28524247
Cancer Manag Res. 2019 Jun 13;11:5473-5480
pubmed: 31354353
J Gynecol Oncol. 2020 Jan;31(1):e1
pubmed: 31788991
Cancer Manag Res. 2019 May 07;11:4223-4230
pubmed: 31123422
Mol Clin Oncol. 2016 Jun;4(6):1052-1056
pubmed: 27284443
Ann Surg Oncol. 2020 Jun;27(6):1947-1955
pubmed: 31898100
Eur J Surg Oncol. 2018 Jun;44(6):754-759
pubmed: 29422253
Ann N Y Acad Sci. 2008 Sep;1138:233-52
pubmed: 18837903
Cancer Chemother Rep. 1966 Mar;50(3):163-70
pubmed: 5910392
Chin Med J (Engl). 2015 Aug 5;128(15):2084-9
pubmed: 26228223
Gynecol Oncol. 1990 Sep;38(3):352-7
pubmed: 2227547
Gynecol Oncol. 2019 Sep;154(3):554-557
pubmed: 31285082
Am J Clin Oncol. 2018 Dec;41(12):1225-1230
pubmed: 29782361
Oncotarget. 2017 Apr 18;8(16):26057-26065
pubmed: 28199962
Medicine (Baltimore). 2018 Jul;97(30):e11711
pubmed: 30045335
Gynecol Oncol. 2019 Jan;152(1):87-93
pubmed: 30389105
Br J Cancer. 2010 Aug 24;103(5):613-6
pubmed: 20628380
Eur J Surg Oncol. 2010 Feb;36(2):155-9
pubmed: 19854606
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Gynaecol Obstet. 2019 Apr;145(1):129-135
pubmed: 30656645
Int J Gynecol Cancer. 2012 Mar;22(3):490-7
pubmed: 22367323
Cancer Med. 2016 Aug;5(8):1725-30
pubmed: 27230108
J Cancer Res Clin Oncol. 2019 Aug;145(8):2157-2166
pubmed: 31273512
Crit Rev Oncol Hematol. 2016 Dec;108:164-174
pubmed: 27931835